In nuclear oncology, despite the fast-growing diffusion of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), single-photon emission computed tomography (SPECT) studies can still play an useful clinical role in several applications. The main limitation of SPECT imaging with tumor-seeking agents is the lack of the structural delineation of the pathologic processes they detect; this drawback sometimes renders SPECT interpretation difficult and can diminish its diagnostic accuracy. Fusion with morphological studies can overcome this limitation by giving an anatomical map to scintigraphic data. In the past, software-based fusion of independently performed SPECT and CT images proved to be time-consuming and impractical for routine use. The recent development of dual-modality integrated imaging systems that provide functional (SPECT) and anatomical (CT) images in the same scanning session, with the acquired images coregistered by means of the hardware, has opened a new era in this field. The first reports indicate that SPECT/CT is very useful in cancer imaging because it is able to provide further information of clinical value in several cases. In SPECT, studies of lung cancer and malignant lymphomas using different radiopharmaceutical, hybrid images are of value in providing the correct localization of tumor sites, with a precise detection of the involved organs, and the definition of their functional status, and in allowing the exclusion of disease in sites of physiologic tracer uptake. Therefore, in lung cancer and lymphomas, hybrid SPECT/CT can play a role in the diagnosis of the primary tumor, in the staging of the disease, in the follow-up, in the monitoring of therapy, in the detection of recurrence, and in dosimetric estimations for target radionuclide therapy. © 2006 Elsevier Inc. All rights reserved.

Schillaci, O. (2006). Single-Photon Emission Computed Tomography/Computed Tomography in Lung Cancer and Malignant Lymphoma. SEMINARS IN NUCLEAR MEDICINE, 36(4), 275-285 [10.1053/j.semnuclmed.2006.05.003].

Single-Photon Emission Computed Tomography/Computed Tomography in Lung Cancer and Malignant Lymphoma

SCHILLACI, ORAZIO
2006-01-01

Abstract

In nuclear oncology, despite the fast-growing diffusion of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET), single-photon emission computed tomography (SPECT) studies can still play an useful clinical role in several applications. The main limitation of SPECT imaging with tumor-seeking agents is the lack of the structural delineation of the pathologic processes they detect; this drawback sometimes renders SPECT interpretation difficult and can diminish its diagnostic accuracy. Fusion with morphological studies can overcome this limitation by giving an anatomical map to scintigraphic data. In the past, software-based fusion of independently performed SPECT and CT images proved to be time-consuming and impractical for routine use. The recent development of dual-modality integrated imaging systems that provide functional (SPECT) and anatomical (CT) images in the same scanning session, with the acquired images coregistered by means of the hardware, has opened a new era in this field. The first reports indicate that SPECT/CT is very useful in cancer imaging because it is able to provide further information of clinical value in several cases. In SPECT, studies of lung cancer and malignant lymphomas using different radiopharmaceutical, hybrid images are of value in providing the correct localization of tumor sites, with a precise detection of the involved organs, and the definition of their functional status, and in allowing the exclusion of disease in sites of physiologic tracer uptake. Therefore, in lung cancer and lymphomas, hybrid SPECT/CT can play a role in the diagnosis of the primary tumor, in the staging of the disease, in the follow-up, in the monitoring of therapy, in the detection of recurrence, and in dosimetric estimations for target radionuclide therapy. © 2006 Elsevier Inc. All rights reserved.
2006
Pubblicato
Rilevanza internazionale
Articolo
Nessuno
Settore MED/50 - SCIENZE TECNICHE MEDICHE APPLICATE
English
depreotide tc 99m; gallium 67; gallium citrate ga 67; iodine 131; pentetreotide in 111; rituximab; technetium 99m; tetrofosmin; yttrium 90; cancer grading; cancer staging; clinical trial; computer assisted tomography; disease severity; dosimetry; drug accumulation; drug distribution; drug mechanism; drug uptake; human; lung cancer; lymphoma; review; single photon emission computer tomography; Equipment Design; Humans; Image Enhancement; Image Interpretation, Computer-Assisted; Lung Neoplasms; Lymphoma; Subtraction Technique; Technology Assessment, Biomedical; Tomography, Emission-Computed, Single-Photon; Tomography, X-Ray Computed
Schillaci, O. (2006). Single-Photon Emission Computed Tomography/Computed Tomography in Lung Cancer and Malignant Lymphoma. SEMINARS IN NUCLEAR MEDICINE, 36(4), 275-285 [10.1053/j.semnuclmed.2006.05.003].
Schillaci, O
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/26918
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 24
  • ???jsp.display-item.citation.isi??? 20
social impact